The pooled HR for OS in ICIs-treated HCC patients who exhibited an AFP response was 0.41 (95%CI=0.33-0.52, p < 0.001), implying that patients with an AFP response derive greater benefit from ICIs than non-responders. Here, AFP is linked to hepatocellular carcinoma.